Focus on IL-6 Inhibitors for Optimizing Multimodal Management of RA
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
A Real World Approach to Unmet Needs, Patient-Centric Care, Special Populations, and Sequencing Biologic Therapies for Rheumatoid Arthritis (RA)
Course Videos
Video
What is the meta-analysis evidence that earlier therapy for RA is preferable to improve outcomes? What is the conclusion from looking at the medical literature?
Video
Do you monitor leukocyte counts in RA patients taking IL-6 inhibitors?
Do you monitor leukocyte counts in RA patients taking IL-6 inhibitors?
Video
What is efficacy profile of IL-6 inhibitors? How does it compare as monotherapy to methotrexate plus and TNFI? What are the side effects we should monitor?
Video
What trials and meta-analyses evaluating RA patients have used health-related quality of life (HRQoL) as a metric for assessing patient outcomes? Which agents, including IL-6 inhibitors, have been evaluated against this metric, and what are the findings?
Video
In what patient subsets (RA biomarker subsets, obese, undifferentiated RA, high risk RA, poor responders, etc.) do IL-6 inhibitors appear to be most effective? Why?
Video
What is the evidence-based approach to non-responsiveness to a TNFI?
What is the evidence-based approach to non-responsiveness to a TNFI?
Video
What are the critical elements of the current American College of Rheumatology (ACR) Guidelines algorithm for RA? Where does IL-6 inhibition fit into these guidelines?
Video
How do define loss of response to a DMARD-based therapy in RA? What markers do you use? Is remission always the end point?
Video
How precise is our understanding of the comparative effectiveness of targeting different cytokine or immune-mediating signaling systems? How long do the effects of a biologic last?
Video
What side effects should we be on the lookout for in patients treated with IL-6 inhibitors? And how should we manage them?
Video
How do we identify RA patients that are likely to respond to inhibition of TNF vs. those likely to respond to inhibition of IL-6 cytokine?
Video
What biomarkers or clinical or symptomatic metrics have you used to identify those patients who will clearly require biologic therapy as foundational approach?